Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative

Journal of Clinical Investigation

Volumn 100, Issue 10, 1997, Pages 2568-2579

  Pece, Nadia ^a,b   Vera, Sonia ^a,b   Cymerman, Urszula ^a,b   White Jr , Robert I ^c   Wrana, Jeffrey L ^a,b   Letarte, Michelle ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arteriovenous malformations; Hereditary diseases; Monocytes; Transforming growth factor beta receptors; Vascular endothelium

Indexed keywords

ENDOGLIN; MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTERIOVENOUS MALFORMATION; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CELL PROLIFERATION; CHROMOSOME 12Q; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONKEY; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; VASCULAR ENDOTHELIUM;

EID: 0030781148     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119800     Document Type: Article

References (57)

1. Guttmacher, A.E., D.A. Marchuk, and R.I.J. White. 1995. Hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 333:918-924.
2. Plauchu, H., J.-P. de Chadaverian, A. Bideau, and J.-M. Robert. 1989. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am. J. Med. Genet. 32:291-297.
3. Braverman, I.M., A. Keh, and B.S. Jacobson. 1990. Ultrastructure and three-dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J. Investig. Dermatol. 95:422-427.
4. Wirth, J.A., J.S. Pollak, and R.I. White, Jr. 1996. Pulmonary arteriovenous malformations. Curr. Pulmonol. Crit. Care Med. 17:261-298.
5. Shovlin, C.L., A.R. Winstock, A.M. Peters, J.E. Jackson, and J.M.B. Hughes. 1995. Medical complications of pregnancy in hereditary haemorrhagic telangiectasia. Q. J. Med. 88:879-887.
6. Kikuchi, K., M. Kowada, and H. Sasajima. 1994. Vascular malformations of the brain in hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber disease). Surg. Neurol. 41:374-380.
7. Garcia-Monaco, R., W. Taylor, G. Rodesch, H. Alvarez, P. Burrows, P. Coubes, and P. Lasjaunias. 1995. Pial arteriovenous vistula in children as presenting manifestation of Rendu-Osler-Weber disease. Neuroradiology. 37:60-64.
8. Scully, R.E., E.J. Mark, W.F. McNeely, S.H. Ebeling, and L.D. Phillips. 1997. Case records of the Massachusetts general hospital (Case 7-1997). N. Engl. J. Med. 336:641-648.
9. McDonald, M.T., K.A. Papenberg, S. Ghosh, A.A. Glatfelter, B.B. Biesecker, E.A. Helmbold, D.S. Markel, A. Zolotor, W.C. McKinnon, J.L. Vanderstoep, et al. 1994. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat. Genet. 6:197-204.
10. Shovlin, C.L., J.M.B. Hughes, E.G.D. Tuddenham, I. Temperley, Y.F.N. Perembelon, J. Scott, C.E. Seidman, and J.G. Seidman. 1994. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q3. Nat. Genet. 6:205-209.
11. Fernandez-Ruiz, E., S. St-Jacques, T. Bellon, M. Letarte, and C. Bernabeu. 1993. Assignment of the human endoglin gene (END) to chromosome 9q34-qter. Cytogenet. Cell Genet. 64:204-207.
12. McAllister, K.A., K.M. Grogg, D.W. Johnson, C.J. Gallione, M.A. Baldwin, C.E. Jackson. E.A. Helmbold, D.S. Markel, W.C. McKinnon, J. Murrell, et al. 1994. Endoglin, a TGF-β binding protein of endothelial cells is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 8:345-351.
13. Vincent, P., H. Plauchu, J. Hazan, S. Fauré, J. Weissenbach, and J. Godel. 1995. A third locus for hereditary haemorrhagic telangectasia maps to chromosome 12q. Hum. Mol. Genet. 4:945-949.
14. Johnson, D.W., J.N. Berg, C.J. Gallione, K.A. McAllister, J.P. Warner, E.A. Helmbold, D.S. Markel, C.E. Jackson, M.E.M. Porteus, and D.A. Marchuk. 1995. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genet. Res. 5:21-28.
15. Johnson, D.W., J.N. Berg, M.A. Baldwin, C.J. Gallione, I. Marondel, S. Yoon, T.T. Stenzel, M. Speer, M.A. Pericak-Vance, A. Diamond, et al. 1996. Mutations in the activin receptor-like kinase 1 gene in hereditary hemorrhagic telangiectasia type 2. Nat. Genet. 13:189-195.
16. Piantanida, M., E. Buscarini, C. Dellavecchia, A. Minelli, A. Rossi, L. Buscarini, and C. Danesino. 1996. Hereditary haemorrhagic telangiectasia with extensive liver involvement is not caused by either HH1 and HHT2. J. Med. Genet. 33:441-443.
17. McAllister, K.A., F. Lennon, B. Bowles-Biesecker, W.C. McKinnon, E.A. Helmbold, D.S. Markel, C.E. Jackson, A.E. Guttmacher, M.A. Pericak-Vance, and D.A. Marchuk. 1994. Genetic heterogeneity in hereditary haemorrhagic telangiectasia: possible correlation with clinical phenotype. J. Med. Genet. 31:927-932.
18. Heutink, P., T. Haitjema, G.J. Breedveld, B. Janssen, L.A. Sandkuijl, C.J.M. Bontekoe, C.J.J. Westerman, and B.A. Oostra. 1994. Linkage of hereditary haemorrhagic telangiectasia to chromosome 9q34 and evidence for locus heterogeneity. J. Med. Genet. 31:933-936.
19. Berg, J.N., A.E. Guttmacher, D.A. Marchuk, and M.E.M. Porteous. 1996. Clinical heterogeneity in hereditary haemorrhagic telangiectasia: are pulmonary arteriovenous malformations more common in families linked to endoglin? J. Med. Genet. 33:256-257.
20. Gougos, A., and M. Letarte. 1990. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 265: 8361-8364.
21. Lastres, P., T. Bellon, C. Cabanas, F. Sanchez-Madrid, A. Acevedo, A. Gougos, M. Letarte, and C. Bernabeu. 1992. Regulated expression on human macrophages of endoglin, an RGD containing surface antigen. Eur. J. Immunol. 22:393-397.
22. Cheifetz, S., T. Bellón, C. Calés, S. Vera, C Bernabeu, J. Massagué, and M. Letarte. 1992. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 267:19027-19030.
23. Zhang, H. W., A.R.E. Shaw, A. Mak, and M. Letarte. 1996. Endoglin is a component of the TGF-β receptor complex of human pre-B leukemic cells. J. Immunol. 156:565-573.
24. Lastres, P., A. Letamendia, H. Zhang, C. Rius, N. Almendro, L.A. Lopez, C. Langa, A. Fabra, M. Letarte, and C. Bernabeu. 1996. Endoglin modulates cellular responses to TGF-β1. J. Cell Biol. 133:1109-1121.
25. RayChaudury, A., and P.A. D'Amore. 1991. Endothelial cell regulation by TGF-beta. J. Cell. Biochem. 47:224-229.
26. Folkman, J., and P.A. D'Amore. 1996. Blood vessel formation: what is its molecular basis? Cell. 87:1153-1155.
27. Wrana, J.L., L. Attisano, R. Wieser, F. Ventura, and J. Massagué. 1994. Mechanisms of activation of the TGF-β receptor. Nature (Lond.). 370:341-347.
28. Massagué, J., L. Attisano, and J.L. Wrana. 1994. The TGF-β family and its composite receptors. Trends Cell Biol. 4:172-178.
29. Eppert, K., S.W. Sherer, H. Ozcelik, R. Pirone, P. Hoodless, H. Kim, L.C. Tsui, B. Bapat, S. Gallinger, I.L. Andrulis, et al. 1996. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectat carcinoma. Cell. 86:543-552.
30. Attisano, L., J.L. Wrana, E. Montalvo, and J. Massagué. 1996. Activation of signaling by the activin receptor complex. Mol. Cell. Biol. 16:1066-1073.
31. Macías-Silva, M., S. Abdollah, P.A. Hoodless, R. Pirone, L. Attisano, and J.L. Wrana. 1996. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signalling. Cell. 87: 1215-1224.
32. Derynck, R., W.M. Gelbart, R.M. Harland, C.-H. Heldin, S.E. Kern, J. Massagué, D.A. Melton, M. Mlodzik, R.W. Padgett, A.B. Roberts, et al. 1996. Nomenclature: vertebrate mediators of TGFβ family signals. Cell. 87:173.
33. Attisano, L., J. Cárcamo, F. Ventura, F.M.B. Weis, J. Massagué, and J.L. Wrana. 1993. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors. Cell. 75:671-680.
34. ten Dijke, P., H. Yamashita, H. Ichijo, P. Franzen, M. Laiho, K. Miyazono, and C.-H. Heldin. 1994. Characterization of the type I receptors for transforming growth factor β receptor-like and activin. Science (Wash. DC). 264: 101-104.
35. McAllister, K.A., M.A. Baldwin, A.K. Thukkani, C.J. Gallione, J.N. Berg, M.E. Porteus, A.E. Guttmacher, and D.A. Marchuk. 1995. Six novel mutations in the endoglin gene in hereditary hemorrhagic telangiectasia type 1 suggest a dominant-negative effect of receptor function. Hum. Mol. Genet. 4: 1983-1985.
36. Yamaguchi, H., H. Azuma, T. Shigekiyo, and H. Inoue. 1997. A novel missense mutation in the endoglin gene in hereditary hemorrhagic telangiectasia. Thromb. Haemostasis. 77:243-247.
37. Gougos, A., and M. Letarte. 1988. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J. Immunol. 141:1925-1933.
38. Burrows, F.J., E.J. Derbyshire, P.L. Tazzari, P. Amlot, A.F. Gazdar, S.W. King, M. Letarte, E.S. Vitetta, and P.E. Thorpe. 1995. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clinical Cancer Res. 1:1623-1634.
39. St-Jacques, S., U. Cymerman, N. Pece, and M. Letarte. 1994. Molecular characterization and m situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology. 134:2645-2657.
40. Bellón, T., A. Corbi, P. Lastres, C. Calés, M. Cebrián, S. Vera, M. Chefeitz, J. Massagué, M. Letarte, and C. Bernabeu. 1993. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23:2340-2345.
41. Hoodless, P.A., T. Haerry, S. Abdollah, M. Stapleton, M.B. O'Connor, L. Attisano, and J.L. Wrana. 1996. MADR1, a MAD-related protein that functions in BMP2 signaling pathways. Cell. 85:489-500.
42. Quackenbush, E.J., and M. Letarte. 1985. Identification of several cell surface proteins of non-T, non-B acute lymphoblastic leukemia by using monoclonal antibodies. J. Immunol. 134:1276-1285.
43. Gougos, A., and M. Letarte. 1988. Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J. Immunol. 141:1934-1940.
44. Letarte, M., A. Greaves, and S. Vera. 1995. CD105 (endoglin) cluster report. In Leukocyte Typing V: White Cell Differentiation Antigens. S.F. Schlossman, L. Boumsell, W. Gilks, J. Harlan, T. Kishimoto, C. Morimoto, J. Ritz, S. Shaw, R. Silverstein, T. Springer, et al., editors. Oxford University Press, Oxford. 1756-1759.
45. Letarte, M., A. Bourdeau, S. Vera, N. Pece, A. Greaves, F. Dignat-George, M.M.B. Kraling, K. Linask, E. O'Brien, M. Labinaz, et al. 1997. EC2 CD105 Workshop panel report. In Leukocyte Typing VI. Garland Publishing, Inc., London. In press.
46. Pichuantes, S., S. Vera, A. Bourdeau, N. Pece, S. Kumar, E.A. Wayner, and M. Letarte. 1997. Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments. Tissue Antigens. 50:265-276.
47. Massagué, J. 1987. Identification of receptors for type-β transforming growth factor. Methods Enzymol. 146:174-195.
48. Löpez-Casillas, F., J.L. Wrana, and J. Massagué. 1993. Betaglycan prsents ligand to the TGF-β signaling receptor. Cell. 73:1435-1444.
49. Cheifetz, S., H. Hernandez, M. Laiho, P. ten Dijke, K.K. Iwata, and J. Massagué. 1990. Distinct transforming growth factor-β (TGF-β) receptor subsets as determinants of cellular responsiveness to three TGF-β isoforms. J. Biol. Chem. 265:20533-20538.
50. Jennings, J.C., S. Mohan, T.A. Linkhart, R. Widstrom, and D.J. Baylink. 1988. Comparison of the biological effects of TGF beta-1 and TGF beta-2: differential activity in endothelial cells. J. Cell Physiol. 137:167-172.
51. McCarthy, S.A., and R. Bicknell. 1993. Inhibition of vascular endothelial cell growth by activin-A. J. Biol. Chem. 268:23066-23071.
52. Porteous, M.E.M., A. Curtis, O. Williams, D. Marchuk, S.S. Bhattacharya, and J. Burn. 1994. Genetic heterogeneity in hereditary haemorrhagic telangiectasia. J. Med. Genet. 31:925-926.
53. Shapiro, M.B., and P. Senapathy. 1987. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res. 15:7155-7174.
54. Muller, G., J. Behrens, U. Nussbaumer, P. Bohlen, and W. Birchmeier. 1987. Inhibitory action of transforming growth factor β on endothelial cells. Proc. Natl. Acad. Sci. USA. 84:5600-5604.
55. Roberts, A.B., and M.B. Sporn. 1989. Regulation of endothelial cell growth, architecture and matrix synthesis by TGF-β. Am. Rev. Respir. Dis. 140: 1126-1128.
56. Dickson, M.C., J.S. Martin, F.M. Cousins, A.B. Kulkarni, S. Karlsson, and R.J. Akhurst. 1995. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development. 121:1845-1854.
57. Shovlin, C.L. 1997. Molecular defects in rare bleeding disorders: hereditary haemorrhagic telangiectasia. Thromb. Haemostasis. 78:145-150.